Several large clinical studies, the majority of which are cardiovascular outcome trials, indicate that GLP-1 RA therapy is safe and tolerable for people living with T2DM and compromised renal function, and also suggest that GLP-1 RAs may have renoprotective properties
Many people experience some degree of weight regain after stopping Mounjaro unless lifestyle changes are sustained
Now, in Part Two, were excited to share Aestha Clinics comprehensive treatment protocols specifically designed to address these challenges
For women, pregnancy status may also impact which treatments are safest and most effective
The accumulated evidence over recent decades regarding the efficacy of new pharmacological treatments for obesity has positioned the glucagon-like peptide-1 (GLP-1) analogue as a key componentwhether as monoagonists, unimolecular multiagonists, or in combination therapies targeting multiple receptors.1 These drugs have made it possible to achieve previously unthinkable goals in terms of weight reduction and control of various obesity-related comorbidities (Fig
Risks: Gastrointestinal side effects: Like other GLP-1 RAs, tirzepatide can cause gastrointestinal side effects, including nausea, vomiting, diarrhea, and constipation
